BIEL BioElectronics Corp.

BioElectronics Corporation to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com

BioElectronics Corporation to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com

Frederick, MD, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via -- BioElectronics Corporation (OTC: BIEL), a leader in the development and manufacturing of non-invasive electroceuticals, today announced that Sree Koneru, Ph.D., will present at the Pain Management Investor Forum to be held (virtually) this afternoon – the Company’s presentation will be at 1:00 pm Eastern Standard Time and consist of a 20-minute formal description of the Company and its financial position, followed by a 20-minute Q&A session moderated by Noble Capital Markets senior equity research analyst, Gregory Aurand.

The presentation can be accessed by registering (at no cost) for the Investor Forum at ; the investor portal created by Noble. The video webcast will be later archived on Channelchek as part of its C-Suite Series , and on its YouTube channel. .

About BioElectronics:

BioElectronics Corporation is a leader in the development of non-invasive electroceuticals and the maker of disposable, drug-free, therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints and RecoveryRx® devices for chronic and post-operative pain.  For more information, visit  



About Noble Capital Markets, Inc.: 

Noble Capital Markets (“Noble”) is a research driven boutique investment bank that has supported small & microcap companies since 1984. As a FINRA and SEC licensed broker dealer Noble provides institutional-quality equity research, merchant and investment banking, wealth management and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the 16 years. In 2018 Noble launched  - a new investment community dedicated exclusively to small and micro-cap companies and their industries. Channelchek is tailored to meet the needs of self-directed investors and financial professionals. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 emerging growth companies are listed on the site, with growing content including the C-Suite and Virtual Roadshow Series videos, and balanced news.

About Channelchek:

Channelchek (.com) is a comprehensive investor-centric portal -- featuring more than 6,000 emerging growth companies -- that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984.  email: 

Contact:

Paul Knopick

940.262.3584



EN
07/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioElectronics Corp.

 PRESS RELEASE

Sree Koneru, PhD Joins the Board of Directors of BioElectronics Corpor...

Sree Koneru, PhD Joins the Board of Directors of BioElectronics Corporation FREDERICK, Md., Dec. 03, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation ( OTC: BIEL, a developer of medical technology products, today announces that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. "We are honored to welcome Sree Koneru to the Board. Sree brings a rich depth of experience in medical device developm...

 PRESS RELEASE

BioElectronics Corporation's Chairman Updates Investors

BioElectronics Corporation's Chairman Updates Investors Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD. Dear Shareholders, It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant. Current Medical (RecoveryRx) Sales Although our RecoveryRx product is well ac...

 PRESS RELEASE

BioElectronics Corporation Announces the Publication of a Canine Arthr...

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study 96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via -- BioElectronics Corporation ( OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed ...

 PRESS RELEASE

BioElectronics Corporation Announces the Publication of Pilot Study Re...

BioElectronics Corporation Announces the Publication of Pilot Study Results Beneficial Treatment Effect for Phantom and Residual Limb Pain Identified FREDERICK, MD, Feb. 23, 2024 (GLOBE NEWSWIRE) -- via – BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. "Treating intractable postamputation pain with wearable, non-invasive, non-thermal, pulsed shortwave (radiofrequency) therapy: a randomized, double-ma...

 PRESS RELEASE

BioElectronics Chairman Updates Investors

BioElectronics Chairman Updates Investors Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharma FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via – BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD. The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans.  As I have mentioned many times, I believe our strategic m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch